filgrastim biosimilar / Nanjing King-Friend Bio, Meitheal Pharmaceuticals - LARVOL DELTA

Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement for Three Biosimilars in the U.S. (Businesswire) - "Meitheal Pharmaceuticals, Inc...today announced it has expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ('HKF') to market and distribute three biosimilars in the U.S. The agreement covers biosimilars for oncology medications pegfilgrastim and filgrastim...Pegfilgrastim and filgrastim are bone marrow stimulants that support white blood cell production for patients receiving certain cancer treatments."

Commercial • Oncology